BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 38435861)

  • 1. A Case of Epstein-Barr Virus-Negative Post-transplant Lymphoproliferative Disorder in a Solid Organ Transplant Recipient With Untreated Chronic Hepatitis C.
    Asiimwe E; Mead M
    Cureus; 2024 Jan; 16(1):e53323. PubMed ID: 38435861
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A population-based study of 135 lymphomas after solid organ transplantation: The role of Epstein-Barr virus, hepatitis C and diffuse large B-cell lymphoma subtype in clinical presentation and survival.
    Kinch A; Baecklund E; Backlin C; Ekman T; Molin D; Tufveson G; Fernberg P; Sundström C; Pauksens K; Enblad G
    Acta Oncol; 2014 May; 53(5):669-79. PubMed ID: 24164103
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epstein-Barr Virus-Negative Diffuse Large B-Cell Post-transplant Lymphoma in an Epstein-Barr Virus-Positive Recipient.
    Lee C; Vincentelli H; Visuri J; Knight S; Ploeg R
    Cureus; 2021 Sep; 13(9):e18134. PubMed ID: 34567913
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multicenter study of pediatric Epstein-Barr virus-negative monomorphic post solid organ transplant lymphoproliferative disorders.
    Afify ZAM; Taj MM; Orjuela-Grimm M; Srivatsa K; Miller TP; Edington HJ; Dalal M; Robles J; Ford JB; Ehrhardt MJ; Ureda TJ; Rubinstein JD; McCormack S; Rivers JM; Chisholm KM; Kavanaugh MK; Bukowinski AJ; Friehling ED; Ford MC; Reddy SN; Marks LJ; Smith CM; Mason CC
    Cancer; 2023 Mar; 129(5):780-789. PubMed ID: 36571557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Case Report: Non-negligible Epstein-Barr virus-associated posttransplant lymphoproliferative disorders in a lung transplant recipient.
    Hu J; Yu YW; Han DS; Li XJ; Zhang YQ; Cai HL; Xiao YH; Zheng X
    Front Immunol; 2023; 14():1244534. PubMed ID: 37781359
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Host microRNAs are decreased in pediatric solid-organ transplant recipients during EBV+ Post-transplant Lymphoproliferative Disorder.
    Sen A; Enriquez J; Rao M; Glass M; Balachandran Y; Syed S; Twist CJ; Weinberg K; Boyd SD; Bernstein D; Trickey AW; Gratzinger D; Tan B; Lapasaran MG; Robien MA; Brown M; Armstrong B; Desai D; Mazariegos G; Chin C; Fishbein TM; Venick RS; Tekin A; Zimmermann H; Trappe RU; Anagnostopoulos I; Esquivel CO; Martinez OM; Krams SM
    Front Immunol; 2022; 13():994552. PubMed ID: 36304469
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined assessment of Epstein-Barr virus viral capsid antigen and Epstein-Barr virus nuclear antigen-1 serology for post-transplant lymphoproliferative disorder risk stratification in adult solid organ transplant recipients.
    Heldman MR; Edlefsen KL; Pepper G; Kapnadak SG; Rakita RM; Fisher CE; Limaye AP
    Transpl Infect Dis; 2022 Dec; 24(6):e13933. PubMed ID: 36000190
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiviral prophylaxis and the Epstein Barr virus-related post-transplant lymphoproliferative disorder.
    Davis CL; Harrison KL; McVicar JP; Forg PJ; Bronner MP; Marsh CL
    Clin Transplant; 1995 Feb; 9(1):53-9. PubMed ID: 7742583
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epstein-Barr virus-associated risk factors for post-transplant lymphoproliferative disease in pediatric liver transplant recipients.
    Quintero Bernabeu J; Juamperez J; Mercadal-Hally M; Larrarte King M; Gallego Melcon S; Gros Subias L; Sábado Álvarez C; Soler-Palacin P; Melendo Pérez S; Esperalba J; Navarro Jiménez A; Garrido Pontnou M; Camacho Soriano J; Hidalgo Llompart E; Bilbao Aguirre I; Charco Torra R
    Pediatr Transplant; 2022 Sep; 26(6):e14292. PubMed ID: 35466492
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epstein-Barr Virus DNAemia and post-transplant lymphoproliferative disorder in pediatric solid organ transplant recipients.
    Chang YC; Young RR; Mavis AM; Chambers ET; Kirmani S; Kelly MS; Kalu IC; Smith MJ; Lugo DJ
    PLoS One; 2022; 17(10):e0269766. PubMed ID: 36256635
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epidemiology of posttransplantation lymphoproliferative disorder in adult renal transplant recipients.
    Morton M; Coupes B; Roberts SA; Klapper PE; Byers RJ; Vallely PJ; Ryan K; Picton ML
    Transplantation; 2013 Feb; 95(3):470-8. PubMed ID: 23222821
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aggressive Epstein-Barr virus-negative B-cell post-transplant lymphoproliferative disorder in a hepatitis C-negative liver transplant recipient who received a hepatitis C-positive graft: Implications for D+/R- hepatitis C virus seroconversion.
    Kutzler HL; Collins K; Maneckshana B; Rochon C; Einstein M; Mnayer L; Rezuke WN; Sheiner P; Serrano OK
    Transpl Infect Dis; 2019 Oct; 21(5):e13144. PubMed ID: 31291501
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Post-transplant lymphoproliferative disorders, Epstein-Barr virus infection, and disease in solid organ transplantation: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice.
    Allen UD; Preiksaitis JK;
    Clin Transplant; 2019 Sep; 33(9):e13652. PubMed ID: 31230381
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epstein-Barr virus-related post-transplant lymphoproliferative disorder in solid organ transplant recipients.
    San-Juan R; Comoli P; Caillard S; Moulin B; Hirsch HH; Meylan P;
    Clin Microbiol Infect; 2014 Sep; 20 Suppl 7():109-18. PubMed ID: 24475976
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Post-transplant lymphoproliferative disease in liver transplant recipients--Merkur University Hospital single center experience].
    Filipec-Kanizaj T; Budimir J; Colić-Cvrlje V; Kardum-Skelin I; Sustercić D; Naumovski-Mihalić S; Mrzljak A; Kolonić SO; Sobocan N; Bradić T; Dolić ZM; Kocman B; Katicić M; Zidovec-Lepej S; Vince A
    Acta Med Croatica; 2011 Sep; 65 Suppl 1():37-43. PubMed ID: 23126028
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Viral load of EBV DNAemia is a predictor of EBV-related post-transplant lymphoproliferative disorders in pediatric renal transplant recipients.
    Colombini E; Guzzo I; Morolli F; Longo G; Russo C; Lombardi A; Merli P; Barzon L; Murer L; Piga S; Ciofi Degli Atti ML; Locatelli F; Dello Strologo L
    Pediatr Nephrol; 2017 Aug; 32(8):1433-1442. PubMed ID: 28280938
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Co-infection of Cytomegalovirus and Epstein-Barr Virus Diminishes the Frequency of CD56
    Lam JKP; Azzi T; Hui KF; Wong AMG; McHugh D; Caduff N; Chan KH; Münz C; Chiang AKS
    Front Immunol; 2020; 11():1231. PubMed ID: 32625211
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk factors for early-onset and late-onset post-transplant lymphoproliferative disorder in kidney recipients in the United States.
    Quinlan SC; Pfeiffer RM; Morton LM; Engels EA
    Am J Hematol; 2011 Feb; 86(2):206-9. PubMed ID: 21264909
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lymphoproliferative disorders in heart transplant recipients: role of hepatitis C virus (HCV) and Epstein-Barr virus (EBV) infection.
    Buda A; Caforio A; Calabrese F; Fagiuoli S; Pevere S; Livi U; Naccarato R; Burra P
    Transpl Int; 2000; 13 Suppl 1():S402-5. PubMed ID: 11112042
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased levels of circulating Epstein-Barr virus (EBV)-infected lymphocytes and decreased EBV nuclear antigen antibody responses are associated with the development of posttransplant lymphoproliferative disease in solid-organ transplant recipients.
    Riddler SA; Breinig MC; McKnight JL
    Blood; 1994 Aug; 84(3):972-84. PubMed ID: 8043879
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.